Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Melanoma 5Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Cyclophosphamide 31Trastuzumab 30Paclitaxel 28Docetaxel 22Taxes 18Doxorubicin 18Lapatinib 15Radiotherapy 14Capecitabine 14Bevacizumab 13Tamoxifen 12Carboplatin 11Filgrastim 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Chemotherapy, Adjuvant 8exemestane 7Vorinostat 7Letrozole 7Immunohistochemistry 7Gemcitabine 7Anastrozole 7Albumin-Bound Paclitaxel 7pegfilgrastim 6Neoadjuvant Therapy 6Magnetic Resonance Spectroscopy 6Immunoenzyme Techniques 6Goserelin 6Flow Cytometry 6Everolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms, Male × oblimersen × Clear all
NCT00063934 2019-03-05

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
31 enrolled 8 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡